Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (Apoptotic) death of PC-82 human prostate cancer cells

Cancer Research

Volumn 58, Issue 15, 1998, Pages 3299-3306

  Gao, Jin ^a,b   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; GROWTH RATE; GROWTH REGULATION; HORMONAL REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

ANDROGENS; ANIMALS; APOPTOSIS; CELL DIVISION; COLLAGEN; DRUG COMBINATIONS; FEMALE; HUMANS; LAMININ; MALE; MICE; MICE, NUDE; MUTATION; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; PROTEOGLYCANS; RECEPTORS, ANDROGEN; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032145501     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Isaacs, J. T. Role of androgens in prostatic cancer. Vitam. Horm., 49: 433-502, 1994.
2. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H., and Hittmair, A. Androgen receptor status of lymph node metastasis from prostate cancer. Prostate, 28: 129-135, 1996.
3. Visalorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Lallioniemi, O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
4. Koivisto, P., Kononen, J., Palmberg, C., Tammela, T., Hyytinen, E., Isola, J., Trapman, J., Cleutjens, K., Noordzij, A., Visakorpi, T., and Kalliomemi, O. P. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res., 57: 314-319, 1997.
5. Marcelli, M., Tilley, W. D., Zoppi, S., Griffin, J. E., Wilson, J. D., and McPhaul, M. J. Androgen resistance associated with a mutation of the androgen receptor at amino acid 772 (Arg-→Cys) results from a combination of decreased messenger ribonucleic acid levels and impairment of receptor function. J. Clin. Endocrinol. Metab., 73: 318-325, 1991.
6. Choong, C. S., Sturm, M. J., Strophair, J. A., McCulloch, R. K., Tilley, W. D., Leedman, P. J., and Hurley, D. M. Partial androgen insensitivity caused by an androgen receptor mutation at amino acid 907 (Gly-→Arg) that result in decreased ligand binding affinity and reduced androgen receptor messenger ribonucleic acid levels. J. Clin. Endocrinol. Metab., 81: 236-243, 1996.
7. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol., 7: 1541-1550, 1993.
8. Tilley, W. D., Buchana, G., Hickey, T. T., and Bentel, J. M. Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independent. Clin. Cancer Res., 2: 277-285, 1996.
9. Cunha, G. R., and Lung, B. The possible influences of temporal factors in androgenic responsiveness of urogenital tissue recombinants from wild-type and androgen-insensitive (Tfm) mice. J. Exp. Zool., 205: 342-343, 1978.
10. Cunha, G. R., Chung, L. W. K., Shannon, J. M., Taguchi, O., and Fujii, H. Hormone-induced morphogenesis and growth: role of mesenchymal-epithelial interactions. Rec. Prog. Horm. Res., 39: 559-598, 1983.
11. Grant, E. S., Batchelor, K. W., and Habib, F. K. The androgen-independence of primary epithelial cell cultures of the prostate is associated with a down-regulation of androgen receptor gene expression. Prostate, 29: 339-349, 1996.
12. Bayne, C. W., Donnelly, F., Chapman, K., Bollina, P., Buck, C., and Habib, F. K. A novel coculture model for benign prostatic hyperplasia expressing both isoforms of 5α-reductase. J. Clin. Endocrinol. Metab., 83: 206-213, 1998.
13. Hoehn, W., Schroeder, F. H., Reimann, J. F., Joebsis, A. C., and Hermanek, P. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC-82). The Prostate, 1: 95-104, 1980.
14. Van Steenbrugge, G. J., van Donger, J. J. W., Reuvers, P. J., de Jong, F. H., and Schroeder, F. H. Transplantable human prostatic carcinoma (PC-82) in athymic nude mice. I. Hormone dependence and the concentration of androgens in plasma and tumor tissue. Prostate, 11: 195-210, 1987.
15. Van Weerden, W. M. van Kreuningen, A., Elissen, N. M. J., Vermeij, M., de Jong, F. H., van Steenbrugge, G. J., and Schroder, F. H. Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in anthymic nude mice. Prostate, 23: 149-164, 1993.
16. Brinkmann, A. O., Bolt, J., van Steenbrugge, G. J., Kuiper, G. G. J. M., de Boer, W., and Mulder, E. Characterization of androgen receptors in a transplantable human prostatic adenocarcinoma (PC-82). Prostate, 10: 133-143, 1987.
17. Csapo, Z., Brand, K., Wlather, R., and Fokas, K. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostate carcinoma lines in nude mice. J. Urol., 140: 1032-1038, 1988.
18. Wright, G. W., Haley, C. L., Csapo, Z., and fan Steenbrugge, G. J. Immunohistochemical evaluation of the expression of prostate tumor-association markers in the nude mouse human prostate carcinoma heterotransplant lines PC-82, PC-EW, and PC-EG. Prostate, 17: 301-316, 1990.
19. Kyprianou, N., English, H., and Isaacs, J. T. Programmed cell death during regression of the PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990.
20. Lyon, M. F., and Hawkes, S. G. X-linked gene for testicular feminization in the mouse. Nature (Lond.), 227: 1217-1219, 1970.
21. Ilio, K. Y., Sensibar, J. A., and Lee, C. Effect of TGF-β1-TGF-α, and EGF on cell proliferation and cell death in rat ventral prostatic epithelial cells in culture. J. Androl., 16: 482-490, 1995.
22. Berges, R. R., Vukanovic, J., Epstein, J. I., CarMichel, M., Cisek, L., Johnson, D. E., Veltri, R. W., Walsh, P. C., and Isaacs, J. T. Implication of the cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res., 1: 473-480, 1995.
23. Passaniti, A., Isaacs, J. T., Haney, J. A., Adler, S. W., Cujdik, T. J., Long, P. V., and Kleinman, H. K. Stimulation of human prostatic carcinoma tumor growth in athymic mice and control of migration in culture by extracellular matrix. Int. J. Cancer, 51: 318-324, 1992.
24. Baisch, H., and Gerdes, J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet., 20: 387-391, 1987.
25. Cattoretti, G., Becker, M. H. G., Duchrow, M., Schluter, C., Galle, J., and Gerdes, J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1) and (MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol., 168: 357-363, 1992.
26. Falini, B., Flenghi, L., Fagioli, M., Stein, H., Schwarting, R., Riccardi, C., Manocchio, I., Pileri, S., Pelicci, P., and Lanfrancone, L. Evolutionary conservation in various mammalian species of the human proliferation-associated epitope recognized by the Ki-67 monoclonal antibody. J. Histochem. Cytochem., 37: 1471-1478, 1989.
27. Charest, N. J., Zhou, Z-X, Lubahn, D. B., Olsen, K. L., Wilson, E. M., and French, F. S. A frameshift mutation destabilizes androgen receptor messenger RNA in the Tfm mouse. Mol. Endocrinol., 5: 573-581, 1991.
28. He, W. W., Jumar, M. W., and Tindall, D. J. A frame-shift mutation in the androgen receptor gene causes complete androgen insensitivity in the testicular-ferminized mouse. Nucleic Acids Res., 19: 2373-2378, 1991.
29. Kleinman, H. K., McGarvey, M. L., Hassell, J. R., Star, V. L., Cannon, F. B., Lanrie, G. W., and Martin, G. R. Basement membrane complexes with biological activity. Biochemistry, 25: 312-318, 1986.
30. Vukicevics, S., Kleinman, H. K., Luyten, F. P., Roberts, A. B., Roche, N. S., and Reddi, A. H. Identification of multiple active growth factors in basement membrane Matrigel suggests caution in interpretation of cellular activity related to extracellular matrix components. Exp. Cell Res., 202: 1-8, 1992.
31. Kan, M., Wang, F., Kan, M., To, B., Gabriel, J., and Mckeehan, W. L. Divalent cations and heparan sulfate cooperate to control assembly and activity of the fibroblast growth factor receptor complex. J. Biol. Chem., 277: 26143-26148, 1997.
32. Joseph, I. B. J. K., and Isaacs, J. T. Potentiation of the antiandiogenic ability of Linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen responsive prostatic cancers. Cancer Res., 57: 1054-1057, 1997.
33. Saeed, B., Zhang, H., and Ng, S. C. Apoptotic program is initiated but not completed in LNCAP cells in response to growth in charcoal-stripped media. Prostate, 31: 145-152, 1997.
34. Veldscholte, J., Berrevoets, C. A., Ris-Stalpers, C., Kuiper, C. G., Jenster, G., Trapman, J., Brinkmann, A. O., and Mulder, E. The androgen receptor in LNCAP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to androgens. J. Steroid Biochem. Mol. Biol., 41: 665-669, 1992.